[PDF] Top 20 El Arte de Sanar a Las Personas - JOSÉ CARLOS BERMEJO

... The discovery of the immune checkpoint mechanism has contributed greatly to recent advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody ipilimumab was first approved as a therapeutic ... See full document

... Abstract: The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocel- lular carcinoma (HCC) has ... See full document

... advanced hepatocellular carcinoma (HCC) has been focus- ing on overcoming tumor angiogenesis and ...HCC. Future studies should focus on identifying speci fi c markers for human MDSCs and developing ... See full document

... cells, immunotherapy has shed new light on and generated a lot of excitement in the treatment of GBM, especially with clinical trials that are cur- rently ... See full document

... marker genes may provide higher specificity, but the expres- sion of each marker gene usually tests positive in only a small subset of the entire population of primary lung cancer patients. For example, preproGRP is a ... See full document

... cell carcinoma growth and progression in vivo ...cell carcinoma of lung, triple-negative breast cancer, basal cell and ductal carcinoma of the breast, adenocarcinoma of the large intestine, lym- ... See full document

... cell carcinoma antigen recognized by T cells (SART) 1 (7), SART3 (8) and papillomavirus binding factor (9) are expressed in osteosarcoma and provided the rationale to develop cellular therapies in ...cell ... See full document

... FLC has a distinct epidemiology, radiographic appearance, as well as pathologic characteristic than HCC. Most often, patients who present with FLC have an absence of common risk factors seen in classic HCC. While ... See full document

... activation status of engineered T cells and at least partially reverse the dysfunction of T cells; therefore, we might provide a feasible strategy for engineered T cell therapy in solid ... See full document

... Globally, the loss of chickpea productivity due to plant parasitic nematodes is estimated to be 14% (Sasser and Freckman, 1987). Important elements for effective integrated control of plant-parasitic nematodes in ... See full document

... After decades of basic research with many setbacks, artificial intelligence (Ai) has recently obtained significant breakthroughs, enabling computer programs to outperform human interpretation of medical images in very ... See full document

... Vol 11, Issue 9, 2018 Online 2455 3891 Print 0974 2441 ROLE OF HERBAL MEDICINES IN VITILIGO TREATMENT CURRENT STATUS AND FUTURE PERSPECTIVES Radhakrishnan Narayanaswamy1*, Intan Safinar Ismail2 1Bio I[.] ... See full document

... the current market situation shows that the steadily increasing trend towards the smallest products is continuing in the future and thus requires new manufacturing technologies for large-quantity ... See full document

... issues may become a primary concern in clinical decisions for situations where survival benefits with current therapy are modest. For some, the number of days, months, or years given following a diagnosis of ... See full document

... an adult patient with relapsed glioblastoma. 114 Of note, the patient relapsed 6 months later when a tumor did not express the antigen. But the therapy was well tolerated without cytokine release syndrome or severe ... See full document

... VIT is commercially available for honeybee, paper wasp, and yellow jacket (“European”) wasps since these are the commonest causes of venom anaphylaxis worldwide. To our knowledge, immunotherapy products for ant ... See full document

... erential proteins associ- ated with inflamed mucosa in active UC, Poulsen et al. inves- tigated tissue biopsies from active distal UC patients using 2DE and MALDI-TOF MS technology [102]. They com- pared the whole lysate ... See full document

... the future vision of integrated data and systems, and produce much enhanced value to the ...to current discussions about CDM, focusing on topics critical to biopharmaceutical companies having compounds in ... See full document

... To maintain or even increase the reliability of both hospital pharmacists and community pharmacists as pro- fessionals for pharmaceutical care and management, we need to understand the current status and ... See full document

... Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-sm[r] ... See full document